Home  /  Resource Library  /  Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single arm, phase 2 trial

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single arm, phase 2 trial

Results of a study examining the combination for zanubrutinib, obinutuzumab and venetoclax for first line treatment of CLL. (Abstract only)